Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition success ...

TRX-221 is under development for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. The drug candidate acts by targeting epidermal growth factor receptor (EGFR). It is ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

The Barbara Ann Karmanos Cancer Institute in Detroit says the new TheraBionic P1 device, an FDA-approved, at-home treatment, ...

Dr. Gary Luker's study shows that breast cancer can lie dormant for years after treatment, especially in patients on estrogen ...

Intestines suffer a lot of wear and tear in their daily service to digestion, requiring constant renewal of their lining.

Qinshan Nuclear Power Base plant in China has opened its doors, producing medical isotopes using online irradiation.

According to the research, some breast cancer cells can remain dormant in the body for years or even decades after treatment, only to resurface later, leading to a relapse. These findings are ...

Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a ...

Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early ...

In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug ...